close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Optimi Health Corp (OP:OPTHF)

0.2311 -0.0293 (-11.25%)
Streaming Delayed Price Updated: 1:44 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Optimi Health Corp

< Previous 1 2 Next >
Optimi Closes Non-Brokered Private Placement, Here Are The Details
Canadian licensed producer of GMP-grade psilocybin Optimi Health Corp. 
Via Benzinga
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Two Psychedelics Companies Will Study Effects Of Natural Psilocybin And MDMA In Healthy Volunteers
Health Canada receives applications concerning clinical trials on a regular basis.  This time, the licensed producer of natural EU-GMP psilocybin and MDMA Optimi Health Corp. 
Via Benzinga
Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people... 
Via PressReach
Topics Supply Chain
Psychedelic Mushrooms Are Going Global: Supply Deal With UK-Based Wellness Company Moves Forward
Expert functional and magic mushrooms grower Optimi Health Corp. (OTCQX: OPTHF) has signed an agreement with Avida Global, a privately-held UK-based producer of white label products including... 
Via Benzinga
Psychedelics May Make People Less Afraid of Death
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change... 
Via FinancialNewsMedia
Topics Supply Chain
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
With psilocybin among the favorites within psychedelics, 
Via Benzinga
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics
Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog. 
Via Benzinga
Psychedelics Use Among Young Adults Reaches All-Time High
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
Via FinancialNewsMedia
First International Psilocybin Supply Agreement For Optimi Health: Here Are The Details
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that... 
Via Benzinga
Optimi Health Given Green Light To Produce And Distribute MDMA In Canada, The Legal Landscape Ahead
Optimi Health Corp. 
Via Benzinga
Meet Blue Serenity, Canada's First Natural Therapeutic Psilocybin Product For Approved Patients
The Canadian-based company licensed by Health Canada for psychedelic and functional mushrooms production, Optimi Health Corp. 
Via Benzinga
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
What A Collab! Optimi Health & Patient Advocate Thomas Hartle's New Medical Psilocybin Venture
Optimi Health Corp. 
Via Benzinga
New Optimi Supply Agreement: Psilocybin For Phase 1 Trial On Microdosing For Wellbeing, No Hallucinogenic Effects
Canadian psychedelics company Optimi Health Corp. (OTCQX: OPTHF) signed a supply agreement with the Bloom Psychedelic Therapy And Research Centre, a Calgary-based provider of psychedelic-assisted... 
Via Benzinga
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its... 
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Shrooms Move Forward For Palliative Care, Optimi To Supply High-Grade Psilocybin For Private Mental Health Practitioner In CA
Optimi Health Corp. 
Via Benzinga
Optimi Health Signs Two New Supply Agreements In Less Than a Week
Optimi (OPTHF), the Canadian, home-grown mushroom formulations producer has signed not one but two supply deals with different research companies. 
Via Benzinga
Optimi Completes First Grow of Psilocybin Mushrooms, Introduces New Head Of Cultivation
Optimi Health Corp. (OPTHF), the Canadian company that produces homegrown and scalable mushrooms accessible to all, announces big step towards commercialization. It has successfully completed its first... 
Via Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. 
Via Benzinga
Optimi Health Adds Large Portfolio Of Magic Mushrooms Strains To Its Genetic Bank
Optimi Health Corp (OTCQX: OPTHF) acquired thirty-three types of psilocybin and mushroom strains intended for cultivation. 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
Company utilizes green chemistry to stabilize natural product with higher yields Vancouver, BC – October 5, 2021 – Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”),... 
Via FinancialNewsMedia
Topics Intellectual Property
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to... 
Via FinancialNewsMedia
Optimi Health Initiates Pathway to Nasdaq Listing
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today